Reactivation of cutaneous psoriasis during abatacept therapy for spondyloarthropathy

Joint Bone Spine

Volumn 77, Issue 6, 2010, Pages 626-627

  Florent, Amélie ^a   Albert, Christine ^a   Giacchero, Damien ^a   Roux, Christian ^a   Euller Ziegler, Liana ^a  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

Author keywords

Abatacept; Causality; Psoriasis; Reactivation; Spondylarthropathy

Indexed keywords

ABATACEPT; ADALIMUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; CASE REPORT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ERYTHEMA; FEMALE; HUMAN; INFECTION; LABORATORY TEST; LETTER; PHOTOTHERAPY; PSORIASIS; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RECURRENT DISEASE; SKIN BIOPSY; SKIN DEFECT; SPONDYLOARTHROPATHY; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; IMMUNOCONJUGATES; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; PSORIASIS; RECURRENCE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 78649908928     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.09.015     Document Type: Letter

References (10)

1. Cañete J.D., Celis R., Hernández V., et al. Synovial immunopathological changes associated with successful abatacept therapy in a case of severe refractory psoriatic arthritis. Ann Rheum Dis 2010, 69:935-936.
2. Vieira F.J., Callado M.R., Vieira W.P. Abatacept as an option therapy in difficult to treat psoriatic arthritis. Rheumatol Int 2010, 30:849-850.
3. Abrams J.R., Lebwohl M.G., Guzzo C.A., et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999, 103:1243-1252.
4. Olivieri I., D'Angelo S., Mennillo G.A., et al. Abatacept in spondyloarthritis refractory to tumour necrosis factor alpha inhibition. Ann Rheum Dis 2009, 68:151-152.
5. Wendling D., Balblanc J.C., Briançon D., et al. Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy. Joint Bone Spine 2008, 75:315-318.
6. Roux C.H., Brocq O., Leccia N., et al. New-onset psoriatic palmoplantaris pustulosis following infliximab therapy: a class effect?. J Rheumatol 2007, 34:434-437.
7. Kary S., Worm M., Audring H., et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. Ann Rheum Dis 2006, 65:405-407.
8. Chaby G., Andréjak M., Lok C., et al. Psoriasis en goutte induit par étanercept récidivant sous abatacept. Ann Dermatol Venereol 2009, 136(12 Suppl. 1):A321.
9. Sibilia J., Westhovens R. Safety of T-cell co-stimulation modulation with abatacept in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007, 25(5 Suppl. 46):S46-56.
10. Ma H.L., Napierata L., Stedman N., et al. Tumor necrosis factor alpha blockade exacerbates murine psoriasis-like disease by enhancing Th17 function and decreasing expansion of Treg cells. Arthritis Rheum 2010, 62:430-440.